Asundexian Slashes Recurrent Stroke Risk in Phase 3 Trial

Asundexian Slashes Recurrent Stroke Risk in Phase 3 Trial

Asundexian stroke prevention represents a significant advancement for patients following a noncardioembolic ischemic stroke or transient ischemic attack. Clinicians traditionally rely on antiplatelet therapy to manage these high-risk individuals. However, the risk of recurrence remains substantial despite these standard interventions. Consequently, researchers have spent decades searching for a safer, more effective antithrombotic strategy. Notably, this search led to the development of asundexian, a novel oral inhibitor of activated factor XI.

Asundexian Stroke Prevention: Insights from the OCEANIC-STROKE Trial

The Phase 3 OCEANIC-STROKE trial recently provided definitive evidence regarding this novel therapeutic approach. Investigators enrolled over 12,000 patients within 72 hours of a recent event. Specifically, the study included individuals with noncardioembolic ischemic stroke or high-risk TIA. Furthermore, these participants received either 50 mg of asundexian once daily or a placebo. Importantly, all patients continued their planned single or dual antiplatelet therapy. Therefore, the study assessed the additive benefit of factor XIa inhibition.

Clinical Efficacy and Superior Safety Profile

The trial results showed that asundexian significantly lowered the incidence of recurrent ischemic stroke. Specifically, 6.2% of patients in the asundexian group experienced a recurrence compared to 8.4% in the placebo group. This outcome translates to a 26% relative risk reduction. Moreover, the safety data proved equally remarkable for clinicians. The rate of major bleeding remained nearly identical between both treatment arms. Consequently, asundexian effectively uncouples the prevention of thrombosis from the risk of bleeding. This breakthrough suggests a major shift in how we approach secondary prevention.

Frequently Asked Questions

Q1: What is the primary benefit of asundexian for stroke survivors?

Asundexian reduces the risk of recurrent ischemic stroke by approximately 26% when added to standard antiplatelet therapy.

Q2: Does asundexian increase the risk of serious bleeding?

No, the OCEANIC-STROKE trial demonstrated that asundexian does not significantly increase major bleeding risk compared to a placebo.

Q3: How does asundexian work differently from traditional blood thinners?

It inhibits factor XIa, which contributes to harmful clot growth while playing only a minimal role in natural bleeding control.

References

1. Sharma M et al. Asundexian for Secondary Stroke Prevention. N Engl J Med. 2026 Apr 16. doi: 10.1056/NEJMoa2513880. PMID: 41985132.
2. Bayer AG. Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study. Published November 23, 2025.
3. Practical Neurology. Factor XIa Inhibitor Asundexian Shown to Reduce Ischemic Stroke Risk Without Increasing Major Bleeding. Published November 25, 2025.